Evaluation for the efficacy and safety of G-CSF in patients with diffuse large B-cell lymphoma: Observational study

Evaluation for the effect of G-CSF administration when initiating R-CHOP therapy in patients with diffuse large B-cell lymphoma: Observational study using a Japanese real-world database - Database study to evaluate the efficacy and safety of G-CSF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058584

Enrollment

2000

Registered

2025-08-01

Start date

2025-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diffuse large B-cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Hospitalized for DLBCL. - Initiated R-CHOP therapy.

Exclusion criteria

Exclusion criteria: - G-CSF were used between hospitalization for DLBCL and initiation of R-CHOP therapy. - Did not have follow-up period for outcomes. - R-CHOP therapy was initiated within 30 days prior to hospitalization for DLBCL.

Design outcomes

Primary

Measure	Time frame
The change of the second cycle of R-CHOP therapy (start date/dose)	—

Secondary

Measure	Time frame
The presence of febrile neutropenia	—

Countries

Japan

Contacts

Public ContactToshiyuki Tsuchiya

RAD-AR Pharmacoepidemiology group mdv team

tsuchiya@rad-ar.or.jp03-3663-8891

Outcome results